Myeloablative conditioning for hematopoietic stem-cell transplantation in patients with non-malignant diseases [6]

Bone Marrow Transplantation

Volumn 38, Issue 4, 2006, Pages 321-322

  Ringdén, Olle ^a   Svenberg, P ^a   Le Blanc, K ^a   Mattsson, J ^a   Remberger, M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINOPATHY; HOME CARE; HUMAN; INBORN ERROR OF METABOLISM; INTERMETHOD COMPARISON; LETTER; MYELOABLATIVE CONDITIONING; OUTPATIENT CARE; PATIENT SAFETY; PATIENT SELECTION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SURVIVAL RATE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELOABLATIVE AGONISTS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

EID: 33747004715     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705438     Document Type: Letter

References (9)

1. Cesaro S. Will a reduced-toxicity conditioning regimen improve the results of stem cell transplantation in metabolic disease? Bone Marrow Transplant 2006; 37: 615.
2. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
3. Stavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
4. Svennilson J, Ringden O. Is it time to reduce toxicity by non-myeloablative conditioning for allogeneic stem cell transplantation in children? Pediatr Transplant 2000; 4: 247-251.
5. Rao K, Amrolia PJ, Jones A, Cale CM, Naik P, King D et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005; 105: 879-885.
6. Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced-intensity haemopoictic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004; 364: 156-162.
7. Svenberg P, Remberger M, Svennilson J, Mattsson J, Le Blanc K, Gustafsson B et al. Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors. Biol Blood Marrow Transplant 2004; 10: 877-882.
8. Ringden O, Labopin M, Bacigalupo A, Arcese W, Schaefer UW, Willemze R et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 4655-4664.
9. Svahn BM, Remberger M, Myrback KE, Holmberg K, Eriksson B, Hentschke P et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood 2002; 100: 4317-4324.